Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1099059.RAxyKV2qHlyA59t2DAdcBuLIXYtvzzDxPG1x3NrRkU-PM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1099059.RAxyKV2qHlyA59t2DAdcBuLIXYtvzzDxPG1x3NrRkU-PM130_assertion type Assertion NP1099059.RAxyKV2qHlyA59t2DAdcBuLIXYtvzzDxPG1x3NrRkU-PM130_head.
- NP1099059.RAxyKV2qHlyA59t2DAdcBuLIXYtvzzDxPG1x3NrRkU-PM130_assertion description "[This approach has been successfully employed in the clinical approval of crizotinib for the treatment of ALK-rearranged non-small cell lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1099059.RAxyKV2qHlyA59t2DAdcBuLIXYtvzzDxPG1x3NrRkU-PM130_provenance.
- NP1099059.RAxyKV2qHlyA59t2DAdcBuLIXYtvzzDxPG1x3NrRkU-PM130_assertion evidence source_evidence_literature NP1099059.RAxyKV2qHlyA59t2DAdcBuLIXYtvzzDxPG1x3NrRkU-PM130_provenance.
- NP1099059.RAxyKV2qHlyA59t2DAdcBuLIXYtvzzDxPG1x3NrRkU-PM130_assertion SIO_000772 23911227 NP1099059.RAxyKV2qHlyA59t2DAdcBuLIXYtvzzDxPG1x3NrRkU-PM130_provenance.
- NP1099059.RAxyKV2qHlyA59t2DAdcBuLIXYtvzzDxPG1x3NrRkU-PM130_assertion wasDerivedFrom befree-2016 NP1099059.RAxyKV2qHlyA59t2DAdcBuLIXYtvzzDxPG1x3NrRkU-PM130_provenance.
- NP1099059.RAxyKV2qHlyA59t2DAdcBuLIXYtvzzDxPG1x3NrRkU-PM130_assertion wasGeneratedBy ECO_0000203 NP1099059.RAxyKV2qHlyA59t2DAdcBuLIXYtvzzDxPG1x3NrRkU-PM130_provenance.